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The Group B streptococcus (Streptococcus agalactiae) is a pathogen of increasing impor-
tance in human disease. We therefore studied the susceptibility of clinical isolates of S.
agalactiae to penicillin G, erythromycin, azithromycin and clindamycin using National
Committee for Clinical Laboratory Standards methodology, and we also determined the
phenotypes of macrolide-lincosamide susceptibility and the resistance genes implicated
in a group of selected isolates of the different phenotypes. We used 221 isolates collected
between 1997 and 1999 in two Health Authority Areas in Mo´stoles and Granada, Spain.
The minimal concentration for 90% inhibition (MIC90) for penicillin G was 0.12 mg/L and
all the isolates tested were susceptible. One hundred and eighty-five (83.7%) were
susceptible to erythromycin and azithromycin and 191 (86.4%) were susceptible to
miocamycin and clindamycin. Twenty-three isolates (10.4%) had a constitutive MLSB
phenotype, seven (3.2%) an inducible phenotype, and six (2.7%) an M phenotype. All
except one of the MLSB phenotype isolates tested (n¼ 23) carried erm genes; in two strains
with the mef (A) gene, all the M phenotype (n¼ 6) isolates tested carried mef genes, while
erm and mef (A) genes were absent in all the macrolide-lincosamide-susceptible (n¼ 12)
isolates tested. In our environment, resistance to macrolide and lincosamide in S.
agalactiae was present in 10–16% of the isolates. The majority of resistant strains had
the MLSB phenotype.
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The Group B streptococcus (Streptococcus agalac-
tiae) is a pathogen of growing importance in
human pathology. Infections in adults produced
by this pathogen are currently infrequent. There
are few recent publications on this subject and the
majority refer to patients with risk factors such as
diabetes mellitus, neoplasia, or hepatic insuffi-
ciency [1] or extreme age [2]. It has been implicated
in bacteremia, pneumonia, endocarditis, urinary
tract infections, septic arthritis, skin infections,
empyema, gangrene and puerperal infection, but
it is of principal interest as the most important
cause of neonatal sepsis [1,3].
b-Lactam antibiotics, and specifically penicillin
G, have been, and are currently, the treatment of
choice for these processes since their continued use
has not modified the in vitro susceptibility of these
micro-organisms, although in some strains toler-
ance has been reported [4]. However, suspected or
confirmed allergy to penicillin has meant that, in a
number of clinical cases, treatment with penicillins
has to be ruled out, as well as, as a precautionary
measure, all b-lactam agents [1,3].
Since their introduction in the 1950s, resistance
to macrolides and lincosamides remained stable
throughout the world until the middle of the
1990s, when it rose in the USA [4–10]. Two resis-
tance mechanisms have been described: modifica-
tion by methylation of the antibiotic target, the
ribosome, and the active efflux of the antibiotic
across the membrane. Modification of the target is
produced by its alteration when a methylase coded
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by the erm (erythromycin ribosome methylation)
genes introduces two methyl residues in an ade-
nine of 23S rRNA. This mechanism affects 14-, 15-
and 16-membered macrolides and also lincosa-
mides and streptogramin B antibiotics. A second
and recently described gene in Streptococcus pyo-
genes is responsible for the active efflux across the
membrane of 14- and 15-membered macrolides
but not of 16-membered macrolides or lincosa-
mides [11]. Subsequently this gene has been found
in strains of Streptococcus pneumoniae and other
streptococci and is known as the mef(A) (macrolide
efflux) gene. It is thought that it codes a hydro-
phobic protein of the membrane which uses the
energy of the proton pump and actively expels the
antibiotic from the interior of the cell [11].
In view of the few studies performed in Europe
concerning the antibiotic susceptibility of S. aga-
lactiae to macrolides, the main aim of this study is
to ascertain the susceptibility of S. agalactiae strains
to different macrolides and lincosamides, to deter-
mine their phenotypic patterns and their resistant
mechanisms.
Over the period 1997–99 we collected 221 iso-
lates of S. agalactiae. The first group of bacteria was
obtained from clinical samples received by the
Microbiology Service of the Hospital of Mo´stoles
(n¼ 171) and their origin was as follows: 37 from
urine, two from vaginal exudates and seven from
rectal exudates of pregnant women, five from
cerebrospinal fluid, two from urethral exudates,
one from ear exudate, one from conjunctival exu-
date, one from sputum and 41 from blood cultures
(the latter isolated since 1990). The second group of
bacteria (n¼ 50) was from vaginal exudates of
pregnant women treated in the Hospital Virgen
de las Nieves of Granada. Strains were identified
by standard criteria: colonies of Gram-positive
cocci, b-haemolytic on sheep blood agar, catalase
negative, that react with Lancefield group B anti-
serum. All strains were kept frozen at 40 8C in
cryotubes which contained 10% skimmed milk.
The antibiotics tested were: penicillin G (Sigma
Chemical Co., St Louis, MO, USA), a 14-membered
macrolide, erythromycin (Sigma Chemical Co), a
15-membered macrolide, azithromycin (Pfizer
Inc., New York, NY, USA), a 16-membered macro-
lide, miocamycin (diacetyl-midecamicin; Menar-
ini, Barcelona, Spain), and a lincosamide,
clindamycin (Sigma Chemical Co).
The antibiotics were incorporated into medium
in a log2 dilution series from 0.008 to 2 mg/L for
penicillin G and from 0.06 to 64 mg/L for macro-
lides and the lincosamide. The minimum inhibi-
tory concentrations (MICs) of each antibiotic were
determined by the agar dilution method. Mueller–
Hinton agar medium with 5% sheep blood was
used according to the National Committee for Clin-
ical Laboratory Standards (NCCLS) criteria [12].
Inocula were prepared by diluting bacterial sus-
pensions equivalent in turbidity to 0.5 McFarland
standard, to provide approximately 104 colony-
forming units per spot when applied by a Steer’s
replicator (Craft Machine Inc., Chester, PA, USA).
The plates were incubated overnight at 35 8C in
an atmosphere containing 5% carbon dioxide. The
range of interpretative categories for each antibio-
tic were those recommended by NCCLS in the
2000 supplement [13]. The MIC breakpoints for
miocamycin were 1 mg/L for susceptible and
>4 mg/L resistant, as defined by the Comite´ de
l’Antibiogramme de la Societe´ Franc¸aise de Micro-
biologie. Staphylococcus aureus ATCC 29213 and S.
pneumoniae ATCC 49619 were used as quality
control strains.
Discs containing erythromycin (15 mg) or clin-
damycin (2 mg) were used to identify antibiotic-
resistance phenotypes. Different phenotypes of
macrolide-lincosamide-streptogramin B (MLSB)
resistance were recognized in accordance with
the description of Seppa¨la¨ et al. [14]. After 24 h
of incubation at 35 8C, blunting of the clindamycin
inhibition zone proximal to the erythromycin disc
was taken to indicate inducible resistance. Resis-
tance to clindamycin (confirmed by the agar dilu-
tion method) with no blunting of the clindamycin
inhibition zone indicated constitutive resistance.
The recent resistance phenotype, designated M
phenotype, was characterized by susceptibility
to clindamycin with no blunting of the inhibition
zone around the clindamycin disc.
Forty-one selected strains of the different pheno-
types were used to determine the presence of erm
and mef genes: 12 susceptible strains, six with the
M phenotype, and 23 with the MLSB phenotype.
The MLS resistance mechanism was determined
by polymerase chain reaction (PCR) by amplifi-
cation of erm genes, using degenerate erm pri-
mers (E1 5
0-GARATIGGIIIIGGIAAGAGGICA-30;
E2 5
0-AAYTGRTTITTIGTRAA-30). The efflux-pump
mechanism was determined by PCR using primers
and specific conditions for amplification of mefA/E
genes (A/E1 5
0-AGTATCATTAATCACTAGTGC-
30; A/E2 50-TTCTTCTGGTACTAAAAGTGG-30)
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[11]. Positive and negative controls from our
collection were used in all cases. Genomic DNA
for PCR reactions was obtained by the Instagene
matrix system (BioRad, Hercules, CA, USA)
according to the manufacturer’s instructions.
Table 1 shows the range of MIC, MIC50, MIC90,
and the percent susceptible to the five antimicro-
bial agents tested.
Penicillin G was the most active antibiotic with
an MIC90 of 0.12 mg/L. Resistance rates for macro-
lides were 16.3% for erythromycin and azithromy-
cin, as representatives of 14- and 15-membered
macrolides, respectively, 13.6% for miocamycin,
as a representative of a 16-membered macrolide,
and 13.6% for clindamycin, the lincosamide tested.
Of the strains studied, 185 (83.7%) showed a
phenotype susceptible to macrolides-lincosa-
mides, 30 (13.6%) had an MLSB resistance pheno-
type [23 (10.4%) a constitutive phenotype and
seven (3.2%) an inducible phenotype] and six
(2.7%) had an M resistance phenotype.
Forty-one strains were selected for PCR study of
the resistance genes. None of the resistance genes
searched for was found in either of the 12 suscep-
tible strains. In 22 out of 23 strains with the MLSB
phenotype an erm gene was found; in two strains it
was found with the mef (A) gene. In the six strains
with the M phenotype an mef (A) gene was found.
All strains with the MLSB constitutive pheno-
type (n¼ 23) had MIC of >64 mg/L for all the
macrolides and the lincosamide tested, and the
seven strains with the MLSB inducible phenotype
were resistant to erythromycin with MICs of 4 mg/
L, susceptible to clindamycin (MICs of 0.12 mg/L)
and had an intermediate resistance to miocamycin
(MICs of 2 mg/L).
Our findings demonstrate that S. agalactiae iso-
lated from a variety of patients with invasive or
non-invasive infections or from healthy pregnant
woman remain uniformly susceptible to penicillin
G. Although increased use of intrapartum chemo-
prophylaxis, theoretically, may promote the devel-
opment of group B streptococcal resistance to
penicillin, we and other investigators have failed
to identify this phenomenon.
In our review of the literature for penicillin,
erythromycin and clindamycin, the median MICs
remained stable from 1957 to 1995 and these
results have been confirmed by several investiga-
tors with only minor disparities between the MICs,
probably due to methodological differences.
Since 1995, resistance to macrolides and linco-
samides has risen, at least in the USA, where
resistance values to erythromycin vary from 7 to
21% and to clindamycin from 3 to 15% [2,7,9,10].
However, in Europe, there are few data concerning
an important increase in resistance to macrolides
and lincosamide [15,16]. Two very recent papers
[15,16] displayed results similar to ours. Ruess et al.
[15] showed increasing macrolide resistance in
recent years. In our study, with strains very
recently obtained in two Spanish centers, we
found a high percentage of resistance to macro-
lides and lincosamides, similar to that reported in
the USA. The identification of resistant strains
suggests that these agents should be used with
caution in the prophylaxis or treatment of S. aga-
lactiae infection in patients allergic to b-lactams.
Traditionally the macrolides, and specifically
erythromycin, have been considered the treatment
and prophylaxis of choice against S. agalactiae in
patients allergic to b-lactams [3]. The fact that resis-
tance is increasing has led some authors to recon-
sider these criteria and to look for alternatives [1],
recommending clindamycin instead of erythromy-
cin, not only as a result of the increase of strains
with M phenotype, susceptibility to clindamycin
and resistance to erythromycin, but also because
clindamycin crosses the transplacental barrier bet-
ter, reaching higher levels in the fetus [1,10].
Table 1 In vitro susceptibility of 221
recent Streptococcus agalactiae isolates
to penicillin G, clindamycin and
three macrolides
MIC (mg/L)
Antibiotic Range MIC50 MIC90
Susceptibility
rates (%)
Penicillin G 0.03–0.12 0.06 0.12 100
Erythromycin 0.06->64 0.06 8 83.7
Azithromycin 0.06->64 0.06 8 83.7
Miocamycin 0.03->64 0.5 2 86.4
Clindamycin 0.03->2 0.06 1 86.4
MIC breakpoints for susceptibility (mg/L) 0.12 for penicillin G, 0.25 for
erythromycin and clindamycin, 0.5 for azithromycin, and 1 for miocamycin.
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In our environment more than 13% of S. agalac-
tiae strains are resistant to macrolides. The major-
ity of these strains present an MLSB phenotype,
mainly constitutive, due to erm genes and, in con-
trast with the strains of S. pyogenes [17], only 2.7%
of S. agalactiae strains studied present an M phe-
notype of resistance due to the mef (A) gene, which
produces efflux of some antibiotics. These data
oblige us to consider the susceptibility to macro-
lides and lincosamides in each individual strain
before using any of these antibiotics.
Periodic surveillance of the susceptibility of S.
agalactiae to macrolides and lincosamides is there-
fore necessary to promote the appropriate thera-
peutic choices for infections caused by this species,
especially in the groups of patients in whom this
species is important.
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